# A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

> **NCT06589765** · PHASE3 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 800 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HRS-7535 tablet
- **DRUG:** dapagliflozin tablet

## Key facts

- **NCT ID:** NCT06589765
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2026-02-18
- **Final completion:** 2026-07-18
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589765, "A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06589765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*